Private Wealth Partners LLC Decreases Stock Position in Novo Nordisk A/S $NVO

Private Wealth Partners LLC lowered its position in shares of Novo Nordisk A/S (NYSE:NVO) by 59.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,638 shares of the company’s stock after selling 31,955 shares during the period. Private Wealth Partners LLC’s holdings in Novo Nordisk A/S were worth $1,201,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. SG Americas Securities LLC increased its stake in Novo Nordisk A/S by 2,101.5% during the 3rd quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock worth $132,242,000 after buying an additional 2,274,925 shares during the period. Bank of Montreal Can increased its position in shares of Novo Nordisk A/S by 101.4% during the second quarter. Bank of Montreal Can now owns 2,475,300 shares of the company’s stock worth $170,845,000 after acquiring an additional 1,246,467 shares during the last quarter. DAVENPORT & Co LLC lifted its stake in shares of Novo Nordisk A/S by 54.8% in the third quarter. DAVENPORT & Co LLC now owns 2,642,498 shares of the company’s stock worth $146,644,000 after acquiring an additional 935,468 shares in the last quarter. Sustainable Growth Advisers LP lifted its stake in shares of Novo Nordisk A/S by 11.7% in the second quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock worth $427,416,000 after acquiring an additional 649,390 shares in the last quarter. Finally, Baird Financial Group Inc. boosted its holdings in Novo Nordisk A/S by 42.6% in the second quarter. Baird Financial Group Inc. now owns 1,476,673 shares of the company’s stock valued at $101,920,000 after purchasing an additional 441,034 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have issued reports on NVO shares. The Goldman Sachs Group restated a “buy” rating on shares of Novo Nordisk A/S in a report on Thursday, January 22nd. BMO Capital Markets set a $57.00 price target on shares of Novo Nordisk A/S in a research note on Monday. Hsbc Global Res cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. CICC Research began coverage on shares of Novo Nordisk A/S in a report on Friday, January 9th. They set an “outperform” rating and a $73.50 price objective for the company. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $57.79.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Very strong launch demand for Wegovy pill: IQVIA data show the pill tracked over 26,000 U.S. prescriptions in its second full week, signaling rapid uptake that supports revenue upside and market share gains in the obesity market. Novo’s Wegovy pill tracks over 26,000 prescriptions
• Positive Sentiment: Early sales momentum reinforced by reporting of ~18,000 U.S. prescriptions in week one and commentary that demand is “strong out of the gate,” which supports upside to near‑term sales and investor sentiment. Demand for Novo Nordisk’s Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally?
• Neutral Sentiment: Analyst view is mixed — one upgrade highlights first‑mover advantage, strong cash and aggressive U.S. marketing but also flags high valuation and potential for near‑term profit‑taking, leading to a cautious “Hold” posture. Novo Nordisk: Momentum Meets Headwinds Before Earnings (Upgrade)
• Neutral Sentiment: Public profile of Novo’s weight‑loss boom is increasing (e.g., a new Danish theatre piece), which is PR‑positive but not directly material to near‑term financials. New play in Denmark charts Novo Nordisk’s weight loss boom
• Negative Sentiment: Leadership change in China: Senior VP and head of China Christine Zhou will step down at end‑of‑March — a potential disruption given China’s importance for growth and ongoing market expansion. Novo Nordisk’s China President Zhou to step down in March
• Negative Sentiment: Near‑term headwinds flagged: analysts warn of slowing Wegovy/Ozempic momentum, pricing pressure and stronger competition that could limit upside to sales growth and margins into the Q4 earnings release. Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $59.40 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57. Novo Nordisk A/S has a 12 month low of $43.08 and a 12 month high of $93.80. The company has a fifty day moving average price of $53.44 and a two-hundred day moving average price of $54.50. The company has a market cap of $265.23 billion, a PE ratio of 17.27 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The company had revenue of $11.79 billion for the quarter, compared to the consensus estimate of $11.98 billion. Research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.